• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Frazier Lifesciences Acquisition Corporation

    11/22/22 4:16:30 PM ET
    $FLAC
    Business Services
    Finance
    Get the next $FLAC alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39765
    Issuer: Frazier Lifesciences Acquisition Corp
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: Two Union Square, 601 Union St.
    Suite 3200
    Seattle WASHINGTON 98101
    Telephone number: 206-954-5429
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Unit
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2022-11-22 By Tara Petta Vice President
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FLAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      2/15/23 10:14:02 AM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      12/1/22 4:51:17 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13D/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/25/22 1:43:14 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Viking Global Investors Lp

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/25/22 1:35:02 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Topper David Joseph

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:31:11 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Bigham Michael

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:27:56 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance
    • Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

      Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired

      10/28/21 8:00:00 AM ET
      $FLAC
      $ISEE
      $KRYS
      $RCKT
      Business Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLAC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation

      15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      12/2/22 4:30:53 PM ET
      $FLAC
      Business Services
      Finance
    • Frazier Lifesciences Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      11/23/22 4:36:01 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 25-NSE filed by Frazier Lifesciences Acquisition Corporation

      25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/22/22 4:17:19 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance